share_log

Cantor Fitzgerald Maintains Overweight on BridgeBio Pharma, Raises Price Target to $60

Moomoo 24/7 ·  Mar 11 09:16

Cantor Fitzgerald analyst Josh Schimmer maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and raises the price target from $50 to $60.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment